Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Alex R. Shoemaker(Abbott (United States)), Steven W. Elmore(AbbVie (United States)), Scott Ackler(AbbVie (United States)), Jessica Adickes(Abbott Fund), Debra C. Ferguson(AbbVie (United States)), Anatol Oleksijew(Abbott Fund), Marion Refici(Abbott (United States)), Baole Wang(Abbott Fund), Xiufen Yang(Abbott Fund), Steven K. Tahir(Abbott (United States)), Christin Tse(Abbott Fund), Joy Bauch(Abbott Fund), Saul H. Rosenberg(AbbVie (United States)), Michael J. Mitten(Abbott Fund), David J. Frost(Abbott Fund), Stephen W. Fesik(Vanderbilt University), Jacqueline M. O’Connor(Abbott Fund), Kennan C. Marsh(AbbVie (United States))
Cited by 209
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k